This group of infectious disease specialists will contribute to the design and implementation of the company’s clinical development strategy in phage therapy
“We are delighted and honored to be able to cooperate with this group of internationally renowned scientists,” said Didier Hoch, CEO of Pherecydes Pharma. “Our unique approach to phage therapy has been deemed particularly promising by these experts, all of whom are very enthusiastic about joining our fight against antibiotic resistance. With their support, we will be able to implement our ambitious development plan effectively. »
The Board will support Pherecydes Pharma in consolidating its clinical development strategy in phage therapy. It will meet twice a year with a first meeting on September 28, 2022.
To receive all of Pherecydes Pharma’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.